The NeuropathyCommons Podcast

 NEW! The NeuropathyCommons Podcast brings together experts to discuss current topics of interest to patients dealing with peripheral neuropathy. Learn about the latest research and more, from neurologists and scientists working in the field. Listen here, or find us on Apple Podcasts.

 

Episode 2. Clinical Trials in Peripheral Neuropathy: The Search for New Treatments

In the second episode of the NeuropathyCommons Podcasts, your host Dr. Alex Chamessian chats with Dr. Gordon Smith, chair of the Department of Neurology at Virginia Commonwealth University. Dr. Smith is the principal investigator on the TopCSPN clinical trial, which is testing topiramate as a potential treatment for people with cryptogenic peripheral neuropathy associated with metabolic syndrome. Alex talks with Dr. Smith about the trial, new ideas about treating peripheral neuropathy, and how patients can get involved in research. 

 

 

Note: Alex and Dr. Smith discuss the Peripheral Neuropathy Research Registry, an effort to collect patient samples and clinical information to better characterize and understand the causes of and potential treatments for peripheral neuropathy. For more information, see the project of the Foundation for Peripheral Neuropathy.

 
Episode 1. COVID-19 and Neuropathy

In the first episode of the NeuropathyCommons Podcasts, your host Dr. Alex Chamessian chats with Dr. Anne Louise Oaklander, a leading expert on peripheral neuropathy and founder of NeuropathyCommons.org. Learn about this website for patients, and listen to their discussion about neuropathy in the time of a pandemic. What do neuropathy patients need to know about the nerve disease and COVID-19?

 

 

Note: In the podcast, Dr. Chamessian and Dr. Oaklander discuss a new report on how the SARS-CoV-2 virus might enter nerve cells. This paper, and a commentary on the work by Dr. Oaklander, are now published in the peer-reviewed journal PAIN.   

 

Follow the links below to access the publications: 

ACE2 and SCARF expression in human dorsal root ganglion nociceptors: implications for SARS-CoV-2 virus neurological effects.
Shiers S, Ray PR, Wangzhou A, Sankaranarayanan I, Tatsui CE, Rhines LD, Li Y, Uhelski ML, Dougherty PM, Price TJ.
Pain. November 2020.

Clinical significance of angiotensin-converting enzyme 2 receptors for severe acute respiratory syndrome coronavirus 2 (COVID-19) on peripheral small-fiber sensory neurons is unknown today.
Oaklander AL.
Pain. November 2020.  

Preprint:

ACE2 expression in human dorsal root ganglion sensory neurons: implications for SARS-CoV-2 virus-induced neurological effects(link is external).
Shiers S, Ray PR, Wangzhou A, Esteves Tatsui C, Rhines L, Li Y, Uhelski ML, Dougherty PM, Price TJ.
BioRxiv. May 29, 2020.